Difference between revisions of "Ghostwriting"

From Powerbase
Jump to: navigation, search
Line 1: Line 1:
 
{{Template:Pharma_Portal_badge}}  
 
{{Template:Pharma_Portal_badge}}  
  
==Ghost Writing==
+
==Actonel==
 
 
'''Actonel'''
 
  
 
In September 2009, the Guardian reported that a leading British bone specialist is facing disciplinary action over accusations that he was involved in "ghost writing". The [[General Medical Council]] will summon Professor [[Richard Eastell]] from Sheffield University to a committee meeting. He admitted to agreeing to have his name used as first author of a study on the osteoporosis drug [[Actonel]] even though he did not have access to all the data on which the study's conclusions were based. <ref>Bosely, S. [http://www.guardian.co.uk/science/2009/sep/18/doctors-ghost-writing-pharmaceutical-research  British doctor faces action over claims of 'ghost writing' for US drug company]. The Guardian. Accessed on 20 September 2009.</ref>
 
In September 2009, the Guardian reported that a leading British bone specialist is facing disciplinary action over accusations that he was involved in "ghost writing". The [[General Medical Council]] will summon Professor [[Richard Eastell]] from Sheffield University to a committee meeting. He admitted to agreeing to have his name used as first author of a study on the osteoporosis drug [[Actonel]] even though he did not have access to all the data on which the study's conclusions were based. <ref>Bosely, S. [http://www.guardian.co.uk/science/2009/sep/18/doctors-ghost-writing-pharmaceutical-research  British doctor faces action over claims of 'ghost writing' for US drug company]. The Guardian. Accessed on 20 September 2009.</ref>
  
'''Caspper'''
+
==Caspper==
  
 
In September 2009, the Guardian reported that [[GlaxoSmithKline]] hired a ghostwriting programme named [[Caspper]] in which doctors could take credit for medical journal articles written by the company's consultants. According to documents held by a US law firm, the project was aimed at increasing America sales of the antidepressant paroxetine otherwise known as [[Paxil]] in the US and [[Seroxat]] in the UK. <ref>Bosely, S. [http://www.guardian.co.uk/science/2009/sep/18/doctors-ghost-writing-pharmaceutical-research  British doctor faces action over claims of 'ghost writing' for US drug company]. The Guardian. Accessed on 20 September 2009.</ref>
 
In September 2009, the Guardian reported that [[GlaxoSmithKline]] hired a ghostwriting programme named [[Caspper]] in which doctors could take credit for medical journal articles written by the company's consultants. According to documents held by a US law firm, the project was aimed at increasing America sales of the antidepressant paroxetine otherwise known as [[Paxil]] in the US and [[Seroxat]] in the UK. <ref>Bosely, S. [http://www.guardian.co.uk/science/2009/sep/18/doctors-ghost-writing-pharmaceutical-research  British doctor faces action over claims of 'ghost writing' for US drug company]. The Guardian. Accessed on 20 September 2009.</ref>

Revision as of 09:19, 21 September 2009

Pharma badge.jpg This article is part of the Pharma_Portal project of Spinwatch.

Actonel

In September 2009, the Guardian reported that a leading British bone specialist is facing disciplinary action over accusations that he was involved in "ghost writing". The General Medical Council will summon Professor Richard Eastell from Sheffield University to a committee meeting. He admitted to agreeing to have his name used as first author of a study on the osteoporosis drug Actonel even though he did not have access to all the data on which the study's conclusions were based. [1]

Caspper

In September 2009, the Guardian reported that GlaxoSmithKline hired a ghostwriting programme named Caspper in which doctors could take credit for medical journal articles written by the company's consultants. According to documents held by a US law firm, the project was aimed at increasing America sales of the antidepressant paroxetine otherwise known as Paxil in the US and Seroxat in the UK. [2]

Notes

  1. Bosely, S. British doctor faces action over claims of 'ghost writing' for US drug company. The Guardian. Accessed on 20 September 2009.
  2. Bosely, S. British doctor faces action over claims of 'ghost writing' for US drug company. The Guardian. Accessed on 20 September 2009.